Cancer costs: Marketing and myth busting

More than half of cancer drugs approved in recent years may not be helping patients to live longer. Meanwhile, the average price of cancer drugs has been increasing by 10 percent annually for more...

Sizing up the FDA’s revolving door with industry

When reviewers with the Food and Drug Administration weigh the evidence for a drug company's experimental treatment, how many are thinking: I may someday work for that company? It's a difficult...

Cancer patient testimonials often tied to drug company money

Speakers who nominally represent cancer patients at advisory meetings on new drugs often have financial ties with the company seeking marketing approval. And those ties aren’t always disclosed,...